Novo Nordisk A/S (NVO) : During the past 4 weeks, traders have been relatively bearish on Novo Nordisk A/S (NVO), hence the stock is down -10.81% when compared to the S&P 500 during the same period. However, in the past 1 week, the selling of the stock is down by -12.83% relative to the S&P 500. The 4-week change in the price of the stock is -8.6% and the stock has fallen -12.46% in the past 1 week.
Novo Nordisk A/S (NYSE:NVO): The stock opened at $49.68 on Friday but the bulls could not build on the opening and the stock topped out at $50.30 for the day. The stock traded down to $48.88 during the day, due to lack of any buying support eventually closed down at $49.87 with a loss of -9.66% for the day. The stock had closed at $55.20 on the previous day. The total traded volume was 7,991,070 shares.
The stock has recorded a 20-day Moving Average of 10.34% and the 50-Day Moving Average is 8.91%. Novo Nordisk A/S has dropped 6.52% during the last 3-month period . Year-to-Date the stock performance stands at -12.62%.
Novo Nordisk A/S is a healthcare company. The Company is engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. It has a range of diabetes product portfolio, including a portfolio of modern insulins as well as a human once-daily GLP-1 analog. It operates in two segments: diabetes care and biopharmaceuticals. The Companys diabetes care segment covers insulins, GLP-1, other protein-related products (such as glucagon, protein-related delivery systems and needles), oral anti-diabetic drugs and obesity. Its biopharmaceuticals segment covers the therapy areas of haemophilia care, growth hormone therapy and hormone replacement therapy. The primary production facilities owned by the Company are located at a number of sites in Denmark, and internationally in the United States, France, China and Brazil.